IP Library Granted Patent US 11,111,208
Granted Patent B2
US 11,111,208 · App. 16/899,903 · Granted Sep 7, 2021

Process for the preparation of safinamide mesylate intermediate

Inventors: Ravishanker Kovi (Monroe Township, NJ); Jayaraman Kannappan (Vadodara, IN); Rajesh A Patel (Vadodara, IN); Daxeshkumar Prakashbhai Patel (Vadodara, IN)
Assignee: RK PHARMA SOLUTIONS LLC
C07C231/12C07C45/63C07C45/71C07C303/32C07C47/575C07C237/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,111,208
App. No.
16/899,903
Granted
Sep 7, 2021
Kind
B2
Abstract

The present application provides methods for the synthesis of intermediates in the synthesis of Safinamide or a pharmaceutically acceptable salt thereof herein Safinamide Mesylate, that is substantially free of impurities.

Claims (17)

1. A method for the preparation of a compound, comprising:

a condensation reaction of 4-hydroxybenzaldehyde of formula II with 1-(chloromethyl)-3-fluorobenzene of formula III, using potassium carbonate, and potassium iodide in a solvent, and removing the solvent after completion of the condensation reaction, therewith producing crude 4-((3-fluorobenzyl)oxy)benzaldehyde of formula IV;

treating the crude with n-heptane to remove genotoxic impurities;

dissolving the treated crude in dichloromethane and treating the solution with potassium carbonate; and

treating the treated solution with n-heptane to afford 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V having a purity greater than 99%.

2. The method of claim 1 , wherein the solvent comprises an alcohol selected from the group consisting of methanol, ethanol, isopropanol, and butanol.

3. The method of claim 1 , wherein the solvent comprises a nitrile selected from the group consisting of acetonitrile and propionitrile.

4. The method of claim 1 , wherein the solvent comprises a cyclic ether selected from the group consisting of tetrahydrofuran, furan, and ethylene oxide.

5. The method of claim 1 , wherein the solvent comprises at least one of DMSO (dimethyl Sulfoxide), DMF (dimethylformamide), and DMA (dimethylacetamide).

6. The method of claim 1 , wherein the resulting 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V has a purity of greater than 99.9%.

7. The method of claim 1 , comprising using the pure 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V for the synthesis of safinamide mesylate of formula I.

8. The method of claim 7 , wherein the resulting safinamide mesylate of formula I is crystalline.

9. The method of claim 7 , wherein the resulting safinamide mesylate of formula I has a purity of greater than 99% and is prepared by reacting pure 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V with L-alaninamide hydrochloride in the presence of methanol and sodium cyanoborohydride to get safinamide and further reacting the safinamide with methane sulfonic acid using ethyl acetate as solvent to obtain safinamide mesylate.

10. The method of claim 9 , wherein the resulting safinamide mesylate of formula I has a purity of greater than 99.9%.

11. The method of claim 1 , wherein the resulting crude formula IV, before the first treatment with n-heptane, has a purity of greater than 99%.

12. The method of claim 1 , wherein the resulting crude formula IV, before the first treatment with n-heptane, has a purity of greater than 99.9%.

13. The method of claim 1 , wherein removing the solvent comprises evaporating the solvent under vacuum.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2024
From: RK PHARMA INC.
To: CITIBANK, N.A.
Reel/Frame 067343/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: RK PHARMA SOLUTIONS LLC
To: RK PHARMA INC
Reel/Frame 060263/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2020
From: KOVI, RAVISHANKER; KANNAPPAN, JAYARAMAN; PATEL, RAJESH A; PATEL, DAXESHKUMAR PRAKASHBHAI
To: RK PHARMA SOLUTIONS LLC
Reel/Frame 054708/0286 →
Priority Claims (1)
IN 201921023977 · Jun 17, 2019 · national
Continuity (1)
Related Publication 20210040031A1 · Feb 11, 2021